Last reviewed · How we verify
lipids
lipids is a Small molecule drug developed by National Center for Research Resources (NCRR). It is currently in Phase 1 development.
Lipids are a broad group of organic compounds that include fats, waxes, sterols, and others, with functions such as storing energy, signaling, and acting as structural components of cell membranes. Lipids have applications in various industries, including cosmetics, food, and nanotechnology.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | lipids |
|---|---|
| Sponsor | National Center for Research Resources (NCRR) |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Pharmacokinetic and Subjective Effects of Heated Tobacco Products (NA)
- Genes Involved in Lipid Disorders
- Evaluation of the Efficacy of Iloprost in the Management of Vaso-occlusive Crises in Adult Patients With Sickle Cell Disease (PHASE3)
- Epigenetic Regulation of Human Adipose Tissue Distribution (NA)
- Alesis OSA-1 Obstructive Sleep Apnea Treatment (NA)
- pAF for the Treatment of Osteoarthritis (PHASE1, PHASE2)
- Study of Smith-Lemli-Opitz Syndrome
- Hepatic Lipid Metabolism-Alcohol Use Disorder
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- lipids CI brief — competitive landscape report
- lipids updates RSS · CI watch RSS
- National Center for Research Resources (NCRR) portfolio CI
Frequently asked questions about lipids
What is lipids?
Who makes lipids?
What development phase is lipids in?
Related
- Manufacturer: National Center for Research Resources (NCRR) — full pipeline
- Therapeutic area: All drugs in Metabolic
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing